Siteone Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In South San Franciscocaliforniafounded In 2010The Company Specializes In Developing Innovative Non Opioid Treatments For Pain And Neurological Disorders By Targeting The Peripheral Nervous Systemtheir Lead Candidatestc 004Is A Selective Nav1 8 Inhibitor That Has Shown Promising Results In Phase 1 Clinical Trialsindicating Safety And Rapid Absorption For Effective Pain Management The Leadership Team Includes Co Founder John Mulcahyphdwho Serves As President And Ceoand John Hunterphdthe Chief Scientific Officersiteone Therapeutics Has Secured Funding From Various Organizationsincluding The National Institute On Drug Abuse And The U Sdepartment Of Defensetotaling $27 61 Millionthe Company Is Committed To Advancing Research And Development In The Field Of Pain Managementfocusing On Safer Alternatives To Traditional Opioid Treatments
